LONDON, November 12, 2014 /PRNewswire/ --
Norgine B.V. today announced new data which demonstrate that bowel cleanser MOVIPREP® (2L polyethylene glycol + ascorbate), in a German colorectal cancer screening population, may lead to reduced long-term colorectal cancer treatment costs.[1] The study will be presented today at the International Society for Pharmacoeconomics and Outcomes Research 17th Annual European Congress (ISPOR) in Amsterdam, The Netherlands.
(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
Results from the study show that the cleansing quality of MOVIPREP® is greater than NaPic/MgCit for all segments of the colon (98.0% vs. 57.5%, p<0.0001).[ 2 ] The long-term cost consequence model also predicts that while the use of MOVIPREP® vs. NaPic/MgCit increases the average per-patient cost associated with colonoscopy by €67, MOVIPREP® enables better bowel cleansing which permits the early detection of polyps and adenomas resulting in less progression to colorectal cancer and an average per-patient saving in colorectal cancer treatment costs of €488. The cost consequence model predicts an average overall cost saving of €420 per patient over a 10 year period.
Colorectal cancer is the third most common cancer worldwide and accounts for every seventh case of cancer in Germany.[2] , [3] Screening programmes have reduced the number of deaths caused by colorectal cancer,[4] but the detection and removal of polyps/adenomas during colonoscopy can often be suboptimal.[5]
See full release on http://www.norgine.com
1. Fischbach W, et al. Cost consequence model investigating the impact of bowel cleansing on prevention of colorectal cancer in a German screening population. ISPOR 17th Annual European Congress 2014 abstract #PCN97
2. Kaatsch P, et al. Cancer in Germany 2007/2008, 8th edition 2012.
3. WCRF 2014. Available at: http://wcrf.org/int/cancer-facts-figures/data-specific-cancers/colorectal-cancer-statistics
4. West NJ, et al. Colorectal cancer screening in Europe: differences in approach; similar barriers to overcome. Int J Colorectal Dis 2009:24:731-740
5. Rex DK, et al. Gastroenterology 1997:112:24-28
Charlotte Andrews: Tel: +44-(0)1895-453669, Mob: +44-(0)7714-061485
Peter Martin: Tel: +44-(0)1895-453744, Mob: +44-(0)7799-078744
